Non-Canonical Technical Helper Structural Snapshot Engineers · PIs · Technical Leads

CAIS Architecture & Sal-Meter Technical Snapshot

A fast technical view of the buildable CAIS stack for the Sal-Meter: layer separation, minimal implementation flow, required canonical DOI map, and the engineering checklist needed to scope a research-stage prototype without confusing helper language with canonical authority.

Current public execution order: External Layer-0 → SICS Internal Phase 0 (G-only) → Phase 1 (I-only) → Phase 2a (Twin Mini-Cell) → Phase 2b (G+I human pilot) → LOCK 1 / LOCK 2 review → post-lock SDK and broader opening. This page is research-stage, non-diagnostic, and non-therapeutic. It does not redefine CAIS, Sal-Meter, OE / RE / EE, or VCE / CRI / CFI.
Document Type
Non-canonical technical helper / structural snapshot
Audience
Engineers, principal investigators, technical leads
Public Status
Research-stage · non-diagnostic · non-therapeutic
Authority
Canonical authority remains fixed only in DOI-registered Zenodo and OSF records
Document role

What this page is for

This page answers one concrete builder question: How can we actually scope a CAIS-compliant Sal-Meter prototype without crossing the canonical boundary?

It is a compressed technical landing page for the current CAIS / Sal-Meter build path. It does not create new naming authority, statistical authority, or compliance authority.

CAIS layer stack

Layer stack at a glance

0

Molecular Interface

Consciousness–material interface at the cartridge / chamber level, realized as a signal-producing non-therapeutic interface under controlled conditions.

1

Acquisition & Preprocessing

Hardware-level signal capture, baseline correction, averaging, and low-noise acquisition readiness.

2

Signal Processing

Noise suppression, feature extraction, normalization, and state separation across controlled conditions.

3

Index Computation

Algorithmic conversion of OE / RE / EE features into canonical VCE / CRI / CFI outputs.

4

Interpretation & Governance

Application domain boundaries, research-only claims discipline, compliance limits, and governance rules for allowed public language and downstream usage.

Layer 0 remains a non-therapeutic signal interface. This stack describes how signals move into downstream processing and indices, not clinical meaning.
Minimal implementation flow

Five-step builder path

1

Interface design

Choose aptamer or alternative molecular interface, specify OE / RE / EE hypotheses, and lock base conditions such as buffer, potential, temperature, and timing.

2

Hardware prototype

Build a 1–3 channel measurement bench, confirm acquisition stability, and establish shielding / wiring / bench repeatability.

3

Signal pipeline

Implement filtering, baseline correction, repeat averaging, OE / RE / EE feature extraction, and basic statistics / clustering across states.

4

Index computation & UI

Implement VCE / CRI / CFI exactly as fixed in the canonical layer, and expose them through a loggable dashboard or app surface.

5

Validation experiments

Run repeated measurements across controlled states such as sleep, rest, meditation, or acute stress, and quantify reproducibility before any broader claim surface.

Engineering checklist

What a serious team should have checked

Layer 0 · Interface

  • Molecular hypotheses for OE, RE, and EE are explicitly documented.
  • The chosen interface has been checked against CAIS requirements.

Layer 1 · Hardware

  • At least one channel shows stable, repeatable signals across repeated measurements.
  • Basic stress tests for noise, temperature, and contact resistance have been performed.

Layer 2 · Signal Processing

  • A fixed preprocessing pipeline is implemented and versioned.
  • Signal-pattern differences are confirmed for controlled states rather than anecdotal sessions.

Layer 3 · Indices

  • VCE / CRI / CFI computation logic is cross-checked against the canonical definition layer.
  • All prohibited transformations from the negative-definition layer are actively avoided.

Layer 4 · Governance

  • The team has an internal rule not to make clinical or commercial efficacy claims beyond research scope.
  • Core members have read the compliance boundary and the relevant competition / implementation documents before public communication.